Thangavelu Lakshmi
Overview
Explore the profile of Thangavelu Lakshmi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parameswari R, Lakshmi T
J Biotechnol
. 2022 Sep;
358:128-139.
PMID: 36122597
Microalgae are highly photosynthetic unicellular organism that have increased demand in the recent days owing to the presence of valuable cellular metabolites. They are ubiquitous in terrestrial and aquatic habitats,...
2.
Senthil R, Kavukcu S, Lakshmi T, Gulsah T, Arife Candas A
Int J Artif Organs
. 2022 Aug;
45(12):1021-1027.
PMID: 35993241
Purpose: In this work, a blend of collagen, physiologically clotted fibrin (PCF), and silver nanoparticles (AgNPs) is used to develop a nanobioscaffold (NBS), for their possible application in wound dressing...
3.
Ezhilarasan D, Shree Harini K, Lakshmi T
Oral Oncol
. 2022 Jul;
132:106005.
PMID: 35785745
No abstract available.
4.
Shree Harini K, Ezhilarasan D, Lakshmi T
Oral Oncol
. 2022 Jun;
132:105983.
PMID: 35753264
No abstract available.
5.
Shree Harini K, Ezhilarasan D, Lakshmi T
Oral Oncol
. 2022 Jun;
131:105954.
PMID: 35671689
No abstract available.
6.
Ezhilarasan D, Lakshmi T
Oxid Med Cell Longev
. 2022 May;
2022:9233650.
PMID: 35602098
Nonalcoholic fatty liver disease (NAFLD) defines fat accumulation in the liver, and it is commonly associated with metabolic syndromes like diabetes and obesity. Progressive NAFLD leads to nonalcoholic steatohepatitis (NASH)...
7.
Ezhilarasan D, Lakshmi T, Mallineni S
Nanomedicine (Lond)
. 2022 Mar;
17(24):1855-1869.
PMID: 35311343
Most anticancer drugs often fail in clinical trials due to poor solubility, poor bioavailability, lack of targeted delivery and several off-target effects. Polymeric nanoparticles such as poly(lactide), poly(lactic--glycolic acid), ALB-loading...
8.
Namrata D, Lakshmi T, Rushabh D, Ezhilarasan D
Oral Oncol
. 2022 Mar;
127:105813.
PMID: 35290831
No abstract available.
9.
Elumalai P, Ezhilarasan D, Lakshmi T
Oral Oncol
. 2022 Mar;
127:105801.
PMID: 35255281
No abstract available.
10.
DagliNamrata , Lakshmi T, Rushabh D, Dineshkumar T, Ezhilarasan D
Oral Oncol
. 2022 Feb;
127:105785.
PMID: 35203001
No abstract available.